We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note
Read MoreHide Full Article
Bristol Myers Squibb (BMY - Free Report) closed the most recent trading day at $60.18, moving +0.6% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.78%. Elsewhere, the Dow lost 0.99%, while the tech-heavy Nasdaq lost 2.61%.
Coming into today, shares of the biopharmaceutical company had gained 0.18% in the past month. In that same time, the Medical sector gained 0.26%, while the S&P 500 lost 3.48%.
Market participants will be closely following the financial results of Bristol Myers Squibb in its upcoming release. The company's earnings per share (EPS) are projected to be $1.55, reflecting a 135.23% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $10.69 billion, reflecting a 9.94% fall from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $6.75 per share and revenue of $45.59 billion, indicating changes of +486.96% and -5.6%, respectively, compared to the previous year.
Any recent changes to analyst estimates for Bristol Myers Squibb should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 3.96% lower. At present, Bristol Myers Squibb boasts a Zacks Rank of #3 (Hold).
Investors should also note Bristol Myers Squibb's current valuation metrics, including its Forward P/E ratio of 8.87. This indicates a discount in contrast to its industry's Forward P/E of 19.4.
We can additionally observe that BMY currently boasts a PEG ratio of 2.22. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. By the end of yesterday's trading, the Medical - Biomedical and Genetics industry had an average PEG ratio of 1.57.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 66, placing it within the top 27% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note
Bristol Myers Squibb (BMY - Free Report) closed the most recent trading day at $60.18, moving +0.6% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.78%. Elsewhere, the Dow lost 0.99%, while the tech-heavy Nasdaq lost 2.61%.
Coming into today, shares of the biopharmaceutical company had gained 0.18% in the past month. In that same time, the Medical sector gained 0.26%, while the S&P 500 lost 3.48%.
Market participants will be closely following the financial results of Bristol Myers Squibb in its upcoming release. The company's earnings per share (EPS) are projected to be $1.55, reflecting a 135.23% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $10.69 billion, reflecting a 9.94% fall from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $6.75 per share and revenue of $45.59 billion, indicating changes of +486.96% and -5.6%, respectively, compared to the previous year.
Any recent changes to analyst estimates for Bristol Myers Squibb should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 3.96% lower. At present, Bristol Myers Squibb boasts a Zacks Rank of #3 (Hold).
Investors should also note Bristol Myers Squibb's current valuation metrics, including its Forward P/E ratio of 8.87. This indicates a discount in contrast to its industry's Forward P/E of 19.4.
We can additionally observe that BMY currently boasts a PEG ratio of 2.22. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. By the end of yesterday's trading, the Medical - Biomedical and Genetics industry had an average PEG ratio of 1.57.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 66, placing it within the top 27% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.